Clinical Trial Update: Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of vorinostat in adults with relapsed or refractory advanced Hodgkin lymphoma has completed, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Vorinostat (Zolinza) (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Favorable Prognosis Hodgkin Lymphoma, Adult Lymphocyte Depletion Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2012-09-19